Nasdaq · Healthcare
Verastem, Inc. (VSTM)
As-reported financials and recent SEC filings for Verastem, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$30.9M
Net income
$-209.5M
Net margin
—
Diluted EPS
$-3.02
ROE
-366.2%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $30.9M | $10.0M | — | $2.6M | $2.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $-170.1M | $-115.0M | $-92.1M | $-72.9M | $-61.4M |
| Net income | $-209.5M | $-130.6M | $-87.4M | $-73.8M | $-71.2M |
| Diluted EPS | $-3.02 | $-1.83 | $-1.98 | $-2.29 | $-2.45 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-25
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →8-K2026-06-23
View on EDGAR →1442026-06-22
View on EDGAR →8-K2026-06-17
View on EDGAR →S-82026-05-29
View on EDGAR →1442026-05-27
View on EDGAR →Largest Healthcare peers
Go deeper on VSTM
Search Verastem, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.